Xenon Inhalation for Treatment of Panic Disorder

Nobilis Therapeutics Inc.200 enrolled

Overview

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

200

Conditions

Panic Disorder

Interventions

XenonDRUG

30% xenon, 30% oxygen, and 40% nitrogen

PlaceboDRUG

30% oxygen, and 70% nitrogen

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary diagnosis of panic disorder according to DSM-5. * Male and female patients ≥18 years of age. Exclusion Criteria: * History of schizophrenia, bipolar and other psychotic disorders. * Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma, severe lung disease and/or baseline oxygen saturations \<92% or any other respiratory conditions / diseases that may affect the respiratory function. * Currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms. * Currently undergoing exposure-based psychotherapy for any condition.

Outcomes

Primary Outcomes

PDSS

Panic Disorder Severity Scale

Time frame: Baseline to Week 6

Secondary Outcomes

PHQ-9

Patient Health Questionnaire-9

Time frame: Baseline to Week 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.